A new pill being developed by Revolution Medicines has shown promising results in a trial for pancreatic cancer, with reports indicating it may double survival rates and cut the risk of death. The drug has been described as a potential breakthrough in treating the disease, with some outlets characterizing its impact as unprecedented. The trial's findings suggest a significant improvement in survival rates for some pancreatic cancer patients, although details of the study's methodology and results are not fully specified.